Why Is IOVANCE BIOTHERAPEUT (IOVA) Stock Up Today?
By the Top Tier Newswire AI Desk · September 30, 2026 at 1:05 AM ET · reviewed against 21 wire stories
IOVANCE BIOTHERAPEUT (IOVA) is up +31.48% in the latest session. Our newswire has captured 21 stories on IOVA across 12 sources in the last 36 hours, with AI sentiment reading bullish (avg 66/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why IOVA stock is up today
Iovance Biotherapeutics stock surged 31.48% to $14.45 in a single session, driven by a raised full-year revenue guidance and strong demand for its therapies. The company increased its 2026 revenue forecast by $55 million at the midpoint, citing robust U.S. demand for Amtagvi and Proleukin. This move has positioned the stock as one of the top performers in the biotech sector, bucking broader declines.
What Happened
Iovance Biotherapeutics raised its 2026 revenue guidance to $410, $420 million, a $55 million increase from its previous $350, $370 million range. The company attributed the upward revision to sustained demand for its FDA-approved melanoma treatment Amtagvi and its Proleukin therapy. The guidance raise has been widely cited in recent coverage, with analysts and market participants highlighting the strong performance of the AMTAGVI launch. The stock's rise also comes amid broader biotech weakness, with IOVA and IBRX outperforming the sector in September.
What The Data Shows
The stock has surged 46.6% over the last eight sessions, from $10.25 to $15.03. Unusual options activity has also been observed, with $2.9 million in call premiums compared to $2.8 million in put premiums. The largest single print was $2.8 million. On September 29, 2026, the stock printed 32 fresh 52-week highs. Despite these gains, the stock remains within its 52-week range of $1.76 to $11.16, though it has exceeded that range in recent trading.
What To Watch
The company’s full-year 2026 guidance and continued performance of Amtagvi and Proleukin will be key to sustaining the momentum. Investors should monitor the company’s ability to meet or exceed its new revenue targets as well as broader market sentiment toward biotech stocks.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
AI sentiment, last 36h · averaged over 21 stories · 66/100 bullish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
6h agoStocktwits NewsNEUTRAL 53General
Biotech Lagged The Broader Market In September — Did Retail Favorites SLS, IBRX, VNDA And IOVA Dodge XBI’s Slump?
IOVA surged 77% and IBRX gained 11%, bucking biotech’s decline, while SLS fell 14% and VNDA slipped 7%.
13h agoSeeking AlphaBULLISH 56Analyst
Iovance: The Turnaround Is Priced In, Downgrading To Hold
Iovance Biotherapeutics, Inc. stock surges as AMTAGVI launch beats expectations; FY26 guidance raised. Click here to read this IOVA update.
15h agoSeeking AlphaBULLISH 67Earnings
Iovance hits highest since 2024 as analysts cheer guidance raise
Iovance Biotherapeutics (IOVA) stock jumps as the company raises its full-year revenue to a level above the consensus, implying nearly 60% YoY growth. Read more here.
17h agoCNBCNEUTRAL 50General
Stocks making the biggest moves midday: Carnival, Fair Isaac, Bloom Energy, Iovance Biotherapeutics & more
Here are some of the companies making headlines in midday trading.
17h agoBarron'sBULLISH 73Product/PR
Iovance Stock Surges as Strong Melanoma Drug Demand Drives Growth
18h agoThe FlyBULLISH 68General
Iovance Biotherapeutics rises 27.8%
18h agoMarketChameleonBULLISH 73Earnings
Iovance lifts 2026 revenue outlook by $55 million at the midpoint as Amtagvi and Proleukin demand stays strong
September 29, 2026
Iovance Biotherapeutics raised full-year 2026 revenue guidance to $410–$420 million, a $55 million midpoint increase from its prior $350–$370 million range, citing strong U.S. demand for Amtagvi and Proleukin. The company also highlighted record Q2 2026 product revenue of $99.3 million and an ATC network approaching 100 centers, with at least 110 targeted by year-end 2026.
TD Cowen raises Iovance Biotherapeutics price target on revenue outlook
TD Cowen raises Iovance Biotherapeutics price target on revenue outlook
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →